Brought to you by 
AcelleRX Therapeutics gets $6.9mm through its Series A
13 May 2015
Executive Summary
Cardiovascular-focused AcelleRX Therapeutics has raised $6.9mm through the closing of its Series A venture round. Triathlon Medical Ventures led the financing and was joined by Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, Blue Chip Venture Company, JumpStart, and North Coast Angel Fund.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AcelleRX Therapeutics gets $6.9mm through its Series A
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice